Methods: The course of infection was assessed by scintigraphy wit

Methods: The course of infection was assessed by scintigraphy with (99m)Technetium-abelled leucocytes, Duplex-Doppler ultrasound, angio-computed tomography Cyclopamine nmr (CT) and microbiological examination.

Results: The mean follow-up was 22.8 (+/- 10.1) months. There was a significant decrease in leucocyte accumulation around the graft among all groups (group 1: p = 0.012, group 2: p = 0.006 and group 3: p = 0.021). The postoperative mortality rate in groups 1,2 and 3 was 8%, 23% and 11%, respectively. The postoperative morbidity was 35% in group 2, 16%

in group 1 and 7% in group 3.

Conclusion: Our study suggests that silver-coated prostheses can be as effective as arterial allografts in the treatment of infections of vascular prostheses. (C) 2010 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.”
“Background: Little is known about the threshold level of low-density lipoprotein cholesterol (LDL-C) for statin therapy in acute myocardial infarction (AMI).

Hypothesis: The aim of this study was to investigate the short-term benefit of the statin in post-MI patients with low LDL-C levels.

Methods: Between November 2005 and January 2008, 6866 statin-naive patients were selected from the Korea AMI registry. Major adverse cardiac event (MACE) was defined as a composite of death, recurrent MI,

and revascularizations.

Results: The 6-month 5-Fluoracil supplier MACE and mortality showed a U-shaped curve, with the lowest rate

at 114-122 mg/ dL. Propensity scores for statin use were calculated for patients with LDL-C <= 113 mg/ dL, and they were used to match the patients who received statin (statin user, n = 1031) with those who did not receive it (statin nonuser, n = 1031). The 6-month MACE was not significantly different between statin users and statin nonusers (9.4% vs 11.0%; hazard ratio [HR]: 0.847, 95% confidence interval [CI]: check details 0.646-1.111, P = 0.230), whereas the 6-month mortality was significantly lower in statin users (7.2% vs 9.7%; HR: 0.728, 95% CI: 0.539-0.984, P = 0.039). However, when the analyses were repeated in the patients with LDL-C <= 105 mg/ dL, not only the 6-month MACE (9.5% vs 9.9%; HR: 0.945, 95% CI: 0.700-1.277, P = 0.713) but also the 6-month mortality (7.0% vs 8.7%; HR: 0.793, 95% CI: 0.566-1.111, P = 0.177) was not significantly different between statin users and statin nonusers (n = 876 in each group).

Conclusions: The beneficial effects of statin therapy seem to vanish when LDL-C is below a certain level in AMI patients.”
“Syncope is a transient and abrupt loss of consciousness with complete return to preexisting neurologic function. It is classified as neurally mediated (i.e., carotid sinus hypersensitivity, situational, or vasovagal), cardiac, orthostatic, or neurogenic.

Comments are closed.